Rocket Lab's shares have fallen by 37.63% in the last month, down to $67.35, which is 55.4% below the record set in May. The takeover of Iridium Communications and uncertainty surrounding the Neutron programme have eroded investor confidence.
The stock price of Rocket Lab has experienced a dramatic plunge in recent weeks. After reaching an all-time high of $151 in May, the value closed on Thursday at $67.35, representing a 37.63% drop in the last month and a 55.4% decline from that record. Despite this setback, so far this year the stock still shows a gain of 31.21%, a contrast that reflects the extreme volatility of the value.
Behind the collapse, there is not a single trigger, but rather a buildup of factors. The takeover bid for Iridium Communications, valued at $8 billion and financed with shares and cash, has raised fears of dilution among shareholders. This was compounded by the neutral coverage initiated by analyst Alexander Potter from Piper Sandler, with a target price of $83, at a time when the market was already digesting the integration of Iridium and doubts about the Neutron programme.
The CEO, Peter Beck, executed a stock sale on March 27 as part of a pre-established 10b5-1 plan, a routine move that, in a highly sensitive environment, added additional pressure. Some analysts suggest that part of the punishment is due to profit-taking following SpaceX's IPO, a factor unrelated to Rocket Lab's fundamentals.
The Neutron rocket, the big unknown
The major catalyst that should validate the growth thesis remains the same unknown: the date of the first flight of the Neutron rocket. Following a fuel tank accident during testing in January, the company maintains its target for the fourth quarter of 2026. However, since then there have been few public updates on the status of the hardware. Five commercial missions are already on the waiting list, but none have launched.
The gap between commercial momentum (backed by a record number of launches of the small Electron rocket in the first half of 2026) and the yet-to-be-proven technology is precisely what makes the stock price so vulnerable. The Electron continues to generate stable cash flows, and the order book stands at $2.2 billion, with over $2 billion in available liquidity. But as long as Neutron does not fly, the market discounts a premium for future growth that seems difficult to defend.
Technical indicators in oversold territory
Technical indicators reflect a situation of acute overselling. The RSI fluctuates between 29.8 and 30.9, well below the threshold of 30 that usually anticipates a rebound. The stock is trading 37.4% below its 50-day average and 12.64% below the 200-session average, piercing this last support for the first time in months.
Annualised volatility over 30 days hovers around 98%, a profile more characteristic of leveraged options than of a space industrial value. In previous bear cycles, such as the inflation shock of 2022, the stock lost as much as 83% from its highs. Recent history reminds us that when the market loses patience with Rocket Lab, the declines can be violent.
Wall Street remains optimistic, but cautiously
Despite the debacle, the majority consensus on the street remains positive. Of the 16 analysts covering the stock, 81% rate it as a buy or strong buy, with an average target price of $117. This would imply substantial upside potential from current levels, although this figure reflects more long-term expectations than an immediate guarantee.
The counterpoint is the extreme valuation. The price-to-sales ratio stands at 72.2 times compared to 3.3 times for the S&P 500. This premium can only be sustained if Neutron arrives on time and the integration of Iridium does not divert resources or generate unforeseen costs. Piper Sandler has specifically highlighted those integration and dilution risks, while the lack of transparency regarding the actual status of the rocket leaves a huge space for speculation.
For the investor interested in the stock, the key lies in the next milestone: the second-quarter earnings report, which according to the current financial calendar could occur in early August 2026. Until then, the stock will continue to dance to the tune of every rumour or regulatory update. Without a firm date for the qualification tests of the Neutron, the punishment could continue, although the technical overselling opens the door to a possible short-term rebound.
You may also like
